Guided Digital Self-Hypnosis Solution for Managing Hot Flashes in Patients Undergoing Adjuvant Hormone Therapy
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Patients treated for breast cancer with hormone therapy (HT) suffer from hot flashes. This side effect impacts treatment adherence. Indeed, approximately 50% of women take less than 80% of the prescribed dose, and up to 50% abandon their treatment before the fifth year of prescription, significantly increasing the risk of recurrence. Moreover, these hot flashes strongly impact the quality of life. According to the CANTO study, these hot flashes can persist up to two years after diagnosis, affecting social relationships, return to work, and physical and mental health. Some side effects resulting from HT (sleep disturbances, fatigue, hot flashes) could be alleviated by a non-pharmacological approach involving the patient. Our hypothesis is that a non-pharmacological solution, such as the use of self-hypnosis, could reduce hot flashes and the side effects related to HT or the perception thereof in patients treated for breast cancer. Consequently, this could improve the quality of life and lead to better treatment adherence. The principal objective is to evaluate the effect of daily guided self-hypnosis sessions in reducing hot flashes in patients with non-metastatic breast cancer receiving anti-aromatase hormone therapy. The secondary objectives are to evaluate : * Patient adherence to guided self-hypnosis via a digital solution * Quality of life * Sleep quality * Satisfaction with care * Usability of the digital tool The originality of this clinical trial is the proposal of self-hypnosis sessions over three weeks with three different themes using a digital solution.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Osoba dorosła
- •Ogólny stan zdrowia oceniony jako dobry (WHO ≤ 2)
- •Kobieta przed, w trakcie lub po menopauzie
- •Leczenie raka piersi bez przerzutów
- •Bieżące leczenie hormonalne, z terapią anty-CDK 4/6 lub bez
- •Co najmniej 50 uderzeń gorąca na tydzień lub co najmniej 7 na dzień
- •Dostęp do komputera lub urządzenia do programu autohipnozy
- •Podpisana świadoma zgoda na udział w badaniu
✗ Disqualifies
- •Mężczyzna
- •Problemy ze słuchem
- •Zaburzenia psychiczne lub poznawcze
- •Brak znajomości języka francuskiego
- •Brak diagnozy raka piersi bez przerzutów
- •Niepoddawanie się leczeniu hormonalnemu
- •Mniej niż 50 uderzeń gorąca na tydzień lub mniej niż 7 na dzień
- •Ciąża lub karmienie piersią
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- February 17, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
Institut de Cancerologie de Lorraine
Vandœuvre-lès-Nancy, France
Trial contact
JEAN LOUIS MERLIN, PUPH
CECILE HUIN SCHOHN, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.